Abstract
Elevated intraocular pressure (IOP) is a major risk factor for development of primary open-angle glaucoma (POAG) (1). Ocular instillation of a hypotensive agent has been shown to effectively delay or prevent the onset of POAG in patients with ocular hypertension (2), and reductions in IOP have been associated with delayed progression of both optic nerve damage and visual field defects in patients with glaucoma (3-6). Given these findings, current treatment of POAG consists of reducing IOP either through medical therapies or surgery (1). European Journal of Ophthalmology / Vol. 17 no. 4, 2007 / pp. 521-527
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
